Rejuran in Daegu: seven things to check before choosing a clinic

Rejuran is not one product. It is usually divided into Healer, HB and HB Plus, which differ in what they target and how they feel. The HB line contains hyaluronic acid, so it shows less immediately after injection; HB Plus contains lidocaine, so pain usually eases as the session proceeds.

If the consultation ends with “we'll do Rejuran” and no formulation is named, ask. They are not the same price and not the same result. Details are on the Rejuran product page.

The commonly quoted design is three to four sessions at two to four week intervals. Those numbers have different origins.

• Two-week intervals, three sessions — the protocol the Korean approval phase 3 actually used. That paper has been retracted.
• Four-week intervals — proposed by a 2026 expert opinion paper which states it is based on the authors' clinical experience. Some authors are employed by the manufacturer.
• A trial comparing session counts in humans — we could not find one.

So there is no basis for calling three sessions correct. A clinic that separates what came from a trial from what is convention is the more accurate one.

Rejuran leaves raised points where it was injected. This is a physical swelling of fluid sitting in the dermis, not the nodule seen with particulate products, and the literature reports it settling within a day or two.

How often it happens varies a lot by formulation. In a 2025 split-face trial (15 subjects), embossing occurred in 56.7% with the conventional formulation and 13.3% with an ionization-adjusted one; erythema was 60% versus 40%; injection pain was VAS 5.04 versus 3.39 (p < 0.005). Wrinkle scores (CFGS, GAIS) did not differ between the two.

A clinic that brings these numbers into consultation is at least prepared to tell you that your face on the day is not the result. Detail is in Rejuran bumps: why they form and how long.

This is the most practical item here. Two sentences are still in wide circulation in Korean clinic material: “it passed a phase 3 with 72 enrolled and 70 analysed” and “95.7% improvement”.

The paper those numbers come from (J Korean Med Sci 2014;29(Suppl 3):S201–S209) was retracted in 2016 (notice: same journal, 2016;31(2):330). PubMed lists its publication type as Retracted Publication. And before retraction, its own abstract stated that the primary and secondary efficacy measures showed no statistical significance versus the control.

We were citing that paper on several pages ourselves and corrected all of them in September 2026. The checking method and the other retracted papers are in The citation stays after the paper is gone.

Wherever you consult, ask once: “which paper does that number come from?” If you get an answer you can verify it on PubMed in five minutes. If you do not, that is information too.

Rejuran is not a volumiser. It targets dermal density, texture and the repair environment. If hollow cheeks are the main concern and a Rejuran course is booked anyway, finishing every session will not produce the change you wanted.

So the order matters: what has been lost (density or volume), and how much descent there is, before any product is named. Which skin is a candidate is tabulated in Rejuran in Daegu: which skin suits it.

Layering onto an area that already contains GOURI (liquid PCL), Sculptra (PLLA) or Radiesse (CaHA) deserves caution. Those materials are not dissolved by hyaluronidase, so if a problem appears later the cause cannot be separated.

Rejuran itself degrades, so dissolving does not apply. But a clinic that moves to a plan without asking your treatment history is worth questioning on that point. Family differences are in CellREDM and Re2O vs Rejuran and GOURI and Rejuran.

Reported adverse events in the PN family are generally mild and transient. A 2026 expert opinion paper states that no granuloma or vascular occlusion has been reported in the literature — while the same paper notes the evidence base remains limited.

What matters is not a clinic that says there are no side effects, but one that tells you when to come back. Whether swelling and bumps are within the expected range, and after how many days you should call.

1. What has been lost — dermal density, volume, or descent. Rejuran answers only the first.
2. Then the formulation — pain sensitivity, your schedule after the session, and the area (periocular or full face).
3. Sessions, with the source stated — we suggest three to four sessions at three to four week intervals, and we say plainly that this is the common Korean design rather than a trial result.
4. Bumps and downtime first — starting from the fact that your face on the day is not the result.
5. Declining is also a decision — if volume is the main problem, we do not recommend Rejuran.

What we do not do: we do not present before-and-after photographs as evidence (Medical Service Act Article 56(2)), we do not put prices in these columns, and we do not cite numbers from a retracted paper.

• Rejuran in Daegu: which skin suits it
• Rejuran: where the evidence now stands
• Rejuran bumps: why they form, how long
• Rejuran product page · Five retracted papers

Lee Chi-Hak, Director, Miso Clinic Daegu

4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, Korea (Exit 1, Kyungpook National University Hospital Station)

+82-53-428-2700 · www.clinicmiso.co.kr

• The class, intended use and approval date in Rejuran's original Korean approval document.
• The published molecular weight of Rejuran's PN.
• A trial comparing Healer, HB and HB Plus under the same conditions.
• A trial comparing session counts in humans.
• Any public metric comparing case volume or skill across clinics in Daegu — none exists.